Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
4
80%
Ph phase_2
1
20%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

NCT02373072
terminatedphase_2

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

NCT02847650
completedphase_1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

NCT02224664
completedphase_1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects

NCT02262767
completedphase_1

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

NCT01981694

Clinical Trials (5)

Showing 5 of 5 trials
NCT02373072Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

Completed
NCT02847650Phase 2

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Terminated
NCT02224664Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

Completed
NCT02262767Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects

Completed
NCT01981694Phase 1

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5